ReutersCodex · 实盘不做把握 6/10
北京时间·🕒 发布 18:36:01时区推断·⟳ 抓取 18:41:56·⚡ 决策 07-16 19:05:10 +23m14s·103.0 天前
礼来据报洽购迷幻药开发商 AtaiBeckley，标的盘前大涨约50%
事件方向对 AtaiBeckley（ATAI.US）本身偏利多，但盘前已按并购溢价快速重定价，Reuters 报道称股价已涨约50%，相对约19.7亿美元前收市值已隐含接近30亿美元估值。
📄 原文Reuters↗ 原文
AtaiBeckley (ATAI.O) shares soared 50% premarket on Thursday after a report that Eli Lilly (LLY.N) was in talks to acqu…
不做 AtaiBeckley（ATAI.US）
收购传闻本身利多，但 ATAI 盘前已涨约50%，当前价格已预支较高并购溢价；交易未正式确认且落空回撤风险大，不追。
不做 Compass Pathways（CMPS.US）
只是迷幻药板块 sympathy 跟涨，未被点名为收购标的，缺少可量化公司级催化，不做。
不做 GH Research（GHRS.US）
盘前跟随行业并购预期上涨，但没有自身交易或订单事件，属于主题联动，追高 edge 不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Reuters 转述 Bloomberg 称礼来洽购 AtaiBeckley，最早可在本周公告；该节点已披露盘后 ATAI 大涨约66%。市场反应:ATAI 盘后大涨约66%，LLY 基本持平。
- Bloomberg 称礼来正在洽购 AtaiBeckley，交易可能最快本周宣布，估值基准为约20亿美元市值并带溢价。市场反应:报道前后 ATAI 盘前继续大幅上涨。
- Reuters 进一步报道 ATAI 盘前涨约50%，并列出 CMPS、GHRS 等同行盘前跟涨。市场反应:ATAI 盘前约+50%，CMPS +7%、GHRS +15%。
- Barron's 报道同一 Bloomberg 消息并确认盘前约50%涨幅，说明消息已进入主流财经媒体。市场反应:ATAI 盘前约+50%，LLY 盘前小幅波动。
关键理由
- 事件方向对 AtaiBeckley（ATAI.US）本身偏利多，但盘前已按并购溢价快速重定价，Reuters 报道称股价已涨约50%，相对约19.7亿美元前收市值已隐含接近30亿美元估值。
- 报道仍处于谈判阶段，礼来与 AtaiBeckley 尚未评论；若交易落空，标的回撤风险远大于追入后的剩余套利空间。
- 同行 Compass Pathways（CMPS.US）和 GH Research（GHRS.US）只是行业情绪外溢，未被点名为收购标的，缺少同向、可量化的公司级催化。
主要风险
- 若本周正式公告且价格显著高于盘前隐含估值，ATAI 仍可能继续跳涨，但当前追入属于赌更高报价而非事件初始反应。
- 迷幻药板块近期已受政策和并购预期推动，同行 sympathy 容易高开低走。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-07-16 · 影响 none
内部 KB 未命中该收购消息的有效旧闻或深度敞口资料，未发现能把追高风险降下来的反向确认。
检索:AtaiBeckley BPL-003 Lilly acquisition psychedelic Bloomberg July 2026 - 做多前查反向 · 来源 web · 日期 2026-07-16 · 影响 weakens
多家媒体均强调仍是谈判中且公司未评论；这削弱追入 ATAI 的风险收益比。
检索:ATAI stock premarket Lilly acquisition talks premium deal risk 原文 ↗
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,859 字
AtaiBeckley (ATAI.O) shares soared 50% premarket on Thursday after a report that Eli Lilly (LLY.N) was in talks to acquire the psychedelic drug developer as soon as this week.
Bloomberg News, late on Wednesday, said Lilly was negotiating a deal at a premium, citing people familiar with the matter.
New York-based AtaiBeckley's shares have gained 31% so far this year to give it a market value of $1.97 billion as of Wednesday's close, according to LSEG data.
U.S. President Donald Trump's executive order in April to help speed up access to treatment based on psychedelic drugs had sparked an industrywide rally.
"While the deal could reach more than $2 billion, ongoing talks with additional pharmaceutical companies could support a higher takeout price," said BMO Capital Markets analyst Evan Seigerman.
Lilly shares were flat before the bell.
Eli Lilly and AtaiBeckley were not immediately available for comment outside regular business hours.
Shares of other psychedelic drug developers also rose premarket on Thursday. Compass Pathways (CMPS.O) gained 7%, GH Research (GHRS.O) jumped 15%, Definium Therapeutics (DFTX.O) climbed 6% and Enveric Biosciences (ENVB.O) rose 3%.
AtaiBeckley focuses on psychedelic-based treatments for mental health conditions and is developing BPL-003, an intranasal formulation of 5-MeO-DMT for treatment-resistant depression.
Trump's order is expected to shorten administrative timelines while attracting more capital to the industry, analysts and health experts have said.
RBC Capital Markets analyst Brian Abrahams said the psychedelic sector is likely to continue its rally and is poised to emerge into the mainstream.
Lilly has been on an acquisition spree, especially in the neuroscience space, highlighted by the $7.8 billion buyout of sleep-disorder drugmaker Centessa Pharmaceuticals.
Bloomberg News, late on Wednesday, said Lilly was negotiating a deal at a premium, citing people familiar with the matter.
New York-based AtaiBeckley's shares have gained 31% so far this year to give it a market value of $1.97 billion as of Wednesday's close, according to LSEG data.
U.S. President Donald Trump's executive order in April to help speed up access to treatment based on psychedelic drugs had sparked an industrywide rally.
"While the deal could reach more than $2 billion, ongoing talks with additional pharmaceutical companies could support a higher takeout price," said BMO Capital Markets analyst Evan Seigerman.
Lilly shares were flat before the bell.
Eli Lilly and AtaiBeckley were not immediately available for comment outside regular business hours.
Shares of other psychedelic drug developers also rose premarket on Thursday. Compass Pathways (CMPS.O) gained 7%, GH Research (GHRS.O) jumped 15%, Definium Therapeutics (DFTX.O) climbed 6% and Enveric Biosciences (ENVB.O) rose 3%.
AtaiBeckley focuses on psychedelic-based treatments for mental health conditions and is developing BPL-003, an intranasal formulation of 5-MeO-DMT for treatment-resistant depression.
Trump's order is expected to shorten administrative timelines while attracting more capital to the industry, analysts and health experts have said.
RBC Capital Markets analyst Brian Abrahams said the psychedelic sector is likely to continue its rally and is poised to emerge into the mainstream.
Lilly has been on an acquisition spree, especially in the neuroscience space, highlighted by the $7.8 billion buyout of sleep-disorder drugmaker Centessa Pharmaceuticals.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。